1887
Rapid communication Open Access
Like 0

Abstract

In Navarre, Spain, in May 2022, the seroprevalence of anti-nucleocapsid (N) and anti-spike (S) antibodies of SARS-CoV-2 was 58.9% and 92.7%, respectively. The incidence of confirmed COVID-19 thereafter through July was lower in people with anti-N antibodies (adjusted odds ratio (aOR) = 0.08; 95% confidence interval (CI): 0.05–0.13) but not with anti-S antibodies (aOR = 1.06; 95% CI: 0.47–2.38). Hybrid immunity, including anti-N antibodies induced by natural exposure to SARS-CoV-2, seems essential in preventing Omicron COVID-19 cases.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2022.27.33.2200619
2022-08-18
2022-09-24
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2022.27.33.2200619
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/27/33/eurosurv-27-33-1.html?itemId=/content/10.2807/1560-7917.ES.2022.27.33.2200619&mimeType=html&fmt=ahah

References

  1. Altarawneh HN, Chemaitelly H, Ayoub HH, Tang P, Hasan MR, Yassine HM, et al. Effects of previous infection and vaccination on symptomatic Omicron infections. N Engl J Med. 2022;387(1):21-34. . Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa2203965 https://doi.org/10.1056/NEJMoa2203965  PMID: 35704396 
  2. World Health Organization (WHO). Interim statement on hybrid immunity and increasing population seroprevalence rates. Geneva: WHO; 1 Jun 2022. Available from: https://www.who.int/news/item/01-06-2022-interim-statement-on-hybrid-immunity-and-increasing-population-seroprevalence-rates
  3. Brandal LT, MacDonald E, Veneti L, Ravlo T, Lange H, Naseer U, et al. Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021. Euro Surveill. 2021;26(50):2101147.  https://doi.org/10.2807/1560-7917.ES.2021.26.50.2101147  PMID: 34915975 
  4. Instituto de Salud Pública y Laboral de Navarra. Informe Epidemiológico Semanal 28/2022 (11 al 17 de julio de 2022). [Weekly epidemiological report 28/2022 (11–17 July 2022)]. Pamplona: Instituto de Salud Pública y Laboral de Navarra; 2022. Spanish. Available from: http://www.navarra.es/NR/rdonlyres/3855C06B-B6A2-4E05-BA57-034AB7947A04/481355/InformeEpidemiologicoSemanal28_2022.pdf
  5. Centro de Coordinación de Alertas y Emergencias Sanitarias. Variantes de SARS-CoV-2 en España: linaje BA.2.12.1, BA.4 y BA.5 de Ómicron. [SARS-CoV-2 variants in Spain: Omicron lineages BA.2.12.1, BA.4 and BA.5]. Madrid: Ministerio de Sanidad; 2022. Spanish. Available from: https://www.sanidad.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/20220628-ERR.pdf
  6. European Centre for Disease Prevention and Control (ECDC). Country overview report: week 28 2022. Stockholm: ECDC; 22 Jul 2022. Available from: https://covid19-country-overviews.ecdc.europa.eu/#weekly_surveillance_summary
  7. European Centre for Disease Prevention and Control (ECDC). Epidemiological update: SARS-CoV-2 Omicron sub-lineages BA.4 and BA.5. Stockholm: ECDC; 2022. Available from: https://www.ecdc.europa.eu/en/news-events/epidemiological-update-sars-cov-2-omicron-sub-lineages-ba4-and-ba5
  8. Consejo Interterritorial del Sistema Nacional de Salud. Principales cambios en las Actualizaciones de la Estrategia de Vacunación frente a COVID-19 en España. [Main changes in the updates of the vaccination strategy against COVID-19 in Spain]. Madrid: Ministerio de Sanidad, Consumo y Bienestar Social. [Accessed: 12 Aug 2022]. Spanish. Available from: https://www.sanidad.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/covid19/Actualizaciones_Estrategia_Vacunacion/docs/COVID-19_ActualizacionesTablaResumen_EstrategiaVacunacion.pdf
  9. Health Department, Government of Navarre. Encuesta de seroprevalencia de anticuerpos frente al SARS-CoV-2 en pacientes de atención primaria de Navarra. [Seroprevalence of antibodies against SARS-CoV-2 in Navarre]. Pamplona: Departamento de Salud de Navarra; 2022. Spanish. Available from: http://www.navarra.es/NR/rdonlyres/60EC3E70-CD63-4424-9CED-0382BB32D093/481539/Informe_FINAL_SEROPREVALENCIA_SARSCoV2.pdf
  10. Ward H, Whitaker M, Flower B, Tang SN, Atchison C, Darzi A, et al. Population antibody responses following COVID-19 vaccination in 212,102 individuals. Nat Commun. 2022;13(1):907.  https://doi.org/10.1038/s41467-022-28527-x  PMID: 35173150 
  11. Jones JM, Stone M, Sulaeman H, Fink RV, Dave H, Levy ME, et al. Estimated US infection- and vaccine-induced SARS-CoV-2 seroprevalence based on blood donations, July 2020-May 2021. JAMA. 2021;326(14):1400-9.  https://doi.org/10.1001/jama.2021.15161  PMID: 34473201 
  12. Martínez-Baz I, Trobajo-Sanmartín C, Miqueleiz A, Guevara M, Fernández-Huerta M, Burgui C, et al. Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021. Euro Surveill. 2021;26(39):2100894.  https://doi.org/10.2807/1560-7917.ES.2021.26.39.2100894  PMID: 34596016 
  13. Hall V, Foulkes S, Insalata F, Kirwan P, Saei A, Atti A, et al. Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection. N Engl J Med. 2022;386(13):1207-20.  https://doi.org/10.1056/NEJMoa2118691  PMID: 35172051 
  14. Nordström P, Ballin M, Nordström A. Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden. Lancet Infect Dis. 2022;22(6):781-90.  https://doi.org/10.1016/S1473-3099(22)00143-8  PMID: 35366962 
  15. Martínez-Baz I, Miqueleiz A, Casado I, Navascués A, Trobajo-Sanmartín C, Burgui C, et al. Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection and hospitalisation, Navarre, Spain, January to April 2021. Euro Surveill. 2021;26(21):2100438.  https://doi.org/10.2807/1560-7917.ES.2021.26.21.2100438  PMID: 34047271 
  16. Sentís A, Kislaya I, Nicolay N, Meijerink H, Starrfelt J, Martínez-Baz I, et al. Estimation of COVID-19 vaccine effectiveness against hospitalisation in individuals aged ≥ 65 years using electronic health registries; a pilot study in four EU/EEA countries, October 2021 to March 2022. Euro Surveill. 2022;27(30):2200551.  https://doi.org/10.2807/1560-7917.ES.2022.27.30.2200551  PMID: 35904059 
  17. Suarez Castillo M, Khaoua H, Courtejoie N. Vaccine-induced and naturally-acquired protection against Omicron and Delta symptomatic infection and severe COVID-19 outcomes, France, December 2021 to January 2022. Euro Surveill. 2022;27(16):2200250.  https://doi.org/10.2807/1560-7917.ES.2022.27.16.2200250  PMID: 35451363 
/content/10.2807/1560-7917.ES.2022.27.33.2200619
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error